|
|
Profile
|
Delegates :
Ryu Ogawa |
|
Incorporated :
May 1 , 2013 |
Paid in Capital :
10 Million yen |
Employees :
35 人 |
Address :
OsakiBrightCore 4F 5-5-15, Kitashinagawa, Shinagawa TOKYO
〒141-0001
|
TEL/FAX :
+81-44-400-1894 / |
URL：
http://molcure.com |
Attachment :
 MOLCURE資料.pdf [ 8.4MiB ] |
Mission/Background :
Molcure is antibody-drug-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of patients by developing and providing more effective therapeutics and supportive care products.
Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure we combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies. |
|
Technology & Business
|
Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure we combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Rapid antibody engineering system “Abtracer”
|
Service/Marketing
|
Abtracer is a patent-pending advanced method combining the phage display technique andnext generation sequencing. By using the
|
Contract with pharma for antibody screening
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Our technology is validated through a number of partnerships and clients.
|
|
Alliance strategy
|
We are seeking new partnership opportunities. (Contract screening service, cooperative research, etc)
|
|
|